Blue Water Ventures International, Inc. · OTC:BWVI
Blue Water Ventures International — Psycheceutical — Investor Presentation (February 2022)
28 slides from Blue Water Ventures International's investor presentation, February 2022
Slide 1: Investor Presentation
STATE-OF-THE-ART PSYCHEDELIC DELIVERY TECHNOLOGIES INVESTOR PRESENTATION FEBRUARY 2022
Slide 2: Our Vision
OUR VISION Using patented, cutting-edge delivery technologies to provide safe and effective bioavailable psychedelic pharmaceutical medicines. Investor Presentation | February 2022 | 2
Slide 3: Who We Are
WHO WE ARE The patented technologies from Psycheceutical FDA Drug Development Veterans will significantly advance the medical application Our talented team of industry experts has 100+ of psychedelic compounds by bringing the highest years of combined experience in psychedelics, levels of safety and
Slide 4: The Problem
THE PROBLEM Unsafe Dosing Prevents Widespread Use of Lifesaving Psychedelics Lower bioavailability results in fewer Higher doses are required to achieve the compounds reaching the targeted site. desired effect, yet over-concentration Most compounds don’t easily cross the blood- leads to adverse reac
Slide 5: The Solution: Psycheceutical Technologies
THE SOLUTION: PSYCHECEUTICAL TECHNOLOGIES Psycheceutical is removing barriers to care by employing next-generation patented drug delivery technologies, via systemic and non-systemic routes of administration, to increase the safety and efficacy of psychedelic compounds. Systemic Delivery: Janus Parti
Slide 6: Psycheceutical's Systemic Janus Particles Solution
PSYCHECEUTICAL’S SYSTEMIC JANUS PARTICLES SOLUTION Our patented Janus particles manufacturing process, based on recent breakthrough discoveries at the University of Michigan, can target specific cells and deliver multiple medicines at different times and rates. ! Extremely small size (less than 100n
Slide 7: Patented Janus Particles Manufacturing
PATENTED JANUS PARTICLES MANUFACTURING For the first time ever, Janus particles can now deliver psychedelics and other complementary compounds at scale, in nearly any required size or shape, in a cost-effective and consistent manner. !""#µ$ !""#µ$ Unlimited Sizes Targeted Shapes Layered Particles Pa
Slide 8: Psycheceutical Janus Particles Key Features
PSYCHECEUTICAL JANUS PARTICLES KEY FEATURES Janus Particle Patented Manufacturing Technology ! Issued and pending patents provide worldwide exclusivity ! Excellent product stability provides long shelf life in for manufacturing and sale of products. a wide range of temperature storage conditions. !
Slide 9: Psycheceutical's Non-Systemic Delivery Solution
PSYCHECEUTICAL’S NON-SYSTEMIC DELIVERY SOLUTION Our patented NeuroDirect™ technology delivers neuro-active compounds directly into the nerve tissue via topical application at the back of the neck, bypassing the GI tract and liver to eliminate the unwanted side effects of psychedelic compounds. To sp
Slide 10: Psycheceutical Novel Delivery Key Features
PSYCHECEUTICAL NOVEL DELIVERY KEY FEATURES NeuroDirect! Patented Delivery Technology ! The NeuroDirect™ delivery introduces neuro-affective ! The NeuroDirect™ lower dosage delivery has shown agents directly into nerve tissue, resulting in much lower symptom reduction without significant adverse reac
Slide 11: Compounds & Delivery Methods
COMPOUNDS & DELIVERY METHODS Molecules We Will Work With Delivery Methods KETAMINE PSILOCYBIN IBOGAINE ORAL TOPICAL NASAL MDMA DMT LSD TRANSDERMAL RECTAL Investor Presentation | February 2022 | 11
Slide 12: Team
TEAM MIKE “ZAPPY” ZAPOLIN DR. JULIAN E. BAILES Chief Visionary Officer Principal Medical Advisor Zappy Zapolin is a futurist, psychedelic Dr. Julian E. Bailes is the Chairman of concierge to the stars, and award- the Department of Neurosurgery, Co- winning filmmaker who is dedicated to Director of t
Slide 13: Team
TEAM CHAD HARMAN DR. ANISH TUTEJA Chief Executive Of!cer Chief Science Officer Mr. Harman is a 25-year cannabis and Anish Tuteja is a Professor of Materials health insurance executive possessing Science and Engineering, Chemical unique leadership experience across Engineering, and Macromolecular Sci
Slide 14: Board / Advisory Team
BOARD / ADVISORY TEAM MICHAEL GURIN BRUCE CASSIDY DR. JOHN KUTZKO Board Member Board Member Formulations Advisor Michael Gurin is a 25-year Mr. Cassidy is an iconic Dr. Kutzko has senior- veteran of technology and investor who serves as level operator experience in business development. Executive Ch
Slide 15: Strategic Partnership
STRATEGIC PARTNERSHIP A CATALYST FOR DEVELOPING THERAPIES THAT IMPROVE OUTCOMES ACCELERATING COMMERCIALIZATION OPPORTUNITIES BUSINESS STRATEGIC COMMERCIAL PORTFOLIO DEVELOPMENT PARTNERSHIPS DEVELOPMENT OPTIMIZATION Assist in developing and Focus on preclinical and novel Clinical development, CMC Eva
Slide 16: Coeptis Team
COEPTIS TEAM DAVE MEHALICK GARY CONTE Co-Founder & CEO SVP of Sales and Marketing Dave also founded Steeltown Consulting Prior to joining Coeptis, Gary served as Group, and co-founded American Executive Vice President of Sales and Defense Systems (IPO), World Health Business Development for an indep
Slide 17: Strategic Partnership
STRATEGIC PARTNERSHIP Psycheceutical, Inc. has entered into a partnership with Vici Health Sciences to assist in developing our NeuroDirectTM topical ketamine formulation. Vici Health Sciences are U.S.-based experts in formulation and analytical method development. Vici Health Sciences provides phar
Slide 18: Psycheceutical's Brand Awareness
PSYCHECEUTICAL’S BRAND AWARENESS Featured articles in: Featured Speakers at: Armed With Two Patents, Psycheceutical Licenses Psycheceutical Plans To Transform New Delivery Technologies Psychedelic Drug Delivery for Psychedelics Wonderland:Miami Biotech Company Earns Two Novel Psychedelic Treatment A
Slide 19: A Revolution
A REVOLUTION The Psychedelic Mental Health Revolution Has Begun Currently in Phase 2 clinical trials Currently in Phase 2 clinical trials Currently in Phase 2 clinical trials Currently in Phase 2 clinical trials Psycheceutical's patented delivery technologies will enhance these companies' second-gen
Slide 20: Market Potential
MARKET POTENTIAL Over $100 Billion Global Market for Psychedelics DEPRESSION ADHD ADDICTION $15B $16B $42B Global annual Global annual Substance abuse depression drug sales ADHD drug sales treatment market ANXIETY PAIN SLEEP $5B $52B $28B Global annual Global annual Global annual anxiety drug sales
Slide 21: Notable Industry Investors
NOTABLE INDUSTRY INVESTORS Top Investors Backing Psychedelic Medicines PETER THIEL KEVIN O’LEARY Renowned Venture Capitalist Shark Tank Star The first investor in Facebook, and early Founded and sold software provider The investor in Uber, Airbnb, Bitcoin, etc. His Learning Company for $4.2 billion
Slide 22: Comparable Companies
COMPARABLE COMPANIES Psycheceutical’s patents are extremely unique and defendable against infringement, which protects the company from any direct competition. Psycheceutical finds itself in a mode of “coopetition” since existing companies who are developing pharmaceutical approaches will need our n
Slide 23: Our Strategy
OUR STRATEGY The therapeutic use of psychedelics for depression, PTSD, and more is driving a growing industry. Psycheceutical is poised to capture a significant market share of the billions already spent on mental health conditions. 1 2 3 4 FDA APPROVAL / PORTFOLIO PROOF OF PRE-CLINICAL / PRODUCT SE
Slide 24: Business Model: Capturing Dual Revenue Streams
BUSINESS MODEL: CAPTURING DUAL REVENUE STREAMS Psycheceutical’s unique business model allows us to leverage our assets in two highly profitable sectors: licensing technology & drug development. B2B Channel In-House IP and Drug Development Developing drug delivery technology for Creating and licensin
Slide 25: Timeline of Key Milestones
TIMELINE OF KEY MILESTONES Q3 Seed Capital Raise 2021 • Seed Capital Raise Q4 • Pre-IND Start Q1 • OTC Merger Completed Q3 • Raise next $20-$50MM • Develop regulatory strategy • Finalize NeuroDirect regulatory strategy • R&D NeuroDirect Ketamine • R&D 2nd drug formulation topical formulation • Devel
Slide 26: Use of Funds
USE OF FUNDS Initial Capital Raise - $5MM Second Round Capital - $30MM Corporate / Admin $2MM Regulatory $0.5MM IP / IND Corporate/ Admin $5MM $0.75MM IP / IND $4MM Clinical Trials $22.5MM Public Filing $0.25MM Investor Presentation | January 2022 | 26
Slide 27: Disclaimer
DISCLAIMER This presentation of Psycheceutical, Inc. (the “Company”) is for information only and shall not constitute an offer to buy, sell, issue or the Company’s ability to successfully pursue its acquisition strategy; legislative and regulatory developments; litigation and subscribe for, or the s
Slide 28: Thank You!
THANK YOU! www.psycheceutical.com | info@psycheceutical.com
Psycheceutical — Investor Presentation (February 2022) on 6ix